ZA200604543B - Heterocyclic anti-migraine agents - Google Patents
Heterocyclic anti-migraine agents Download PDFInfo
- Publication number
- ZA200604543B ZA200604543B ZA200604543A ZA200604543A ZA200604543B ZA 200604543 B ZA200604543 B ZA 200604543B ZA 200604543 A ZA200604543 A ZA 200604543A ZA 200604543 A ZA200604543 A ZA 200604543A ZA 200604543 B ZA200604543 B ZA 200604543B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- indazol
- piperidine
- dihydroquinazolin
- ethyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims description 30
- 229940125684 antimigraine agent Drugs 0.000 title description 2
- 239000002282 antimigraine agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 73
- -1 benzfuranyl Chemical group 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 30
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 13
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002541 furyl group Chemical group 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 9
- 125000003368 amide group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- CTOUNZIAEBIWAW-UHFFFAOYSA-N 3,4-dihydro-1h-quinazolin-2-one Chemical compound C1=CC=C2NC(=O)NCC2=C1 CTOUNZIAEBIWAW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 6
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 6
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000004306 triazinyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 2
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 2
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 28
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 14
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 3
- JECMGRSNYXYSNO-UHFFFAOYSA-N 4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1N1C(=O)NC2=CC=CC=C2C1 JECMGRSNYXYSNO-UHFFFAOYSA-N 0.000 claims 2
- BRHJBAIBJSYVCV-UHFFFAOYSA-N 4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1C1=CC2=CC=CC=C2NC1=O BRHJBAIBJSYVCV-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- LHDSOMLOOLRWDD-UHFFFAOYSA-N 1-(1-benzyltetrazol-5-yl)-2-(7-ethyl-3-methyl-2H-indazol-5-yl)ethanamine Chemical compound C=1C2=C(C)NN=C2C(CC)=CC=1CC(N)C1=NN=NN1CC1=CC=CC=C1 LHDSOMLOOLRWDD-UHFFFAOYSA-N 0.000 claims 1
- UVBZRGCVAMHDDP-UHFFFAOYSA-N 2-(7-ethyl-3-methyl-2H-indazol-5-yl)-1-(1-methyltetrazol-5-yl)ethanamine Chemical compound C=1C2=C(C)NN=C2C(CC)=CC=1CC(N)C1=NN=NN1C UVBZRGCVAMHDDP-UHFFFAOYSA-N 0.000 claims 1
- IOAPEXXYJOGIDO-UHFFFAOYSA-N 2-(7-ethyl-3-methyl-2H-indazol-5-yl)-1-(2H-tetrazol-5-yl)ethanamine Chemical compound C=1C2=C(C)NN=C2C(CC)=CC=1CC(N)C=1N=NNN=1 IOAPEXXYJOGIDO-UHFFFAOYSA-N 0.000 claims 1
- DDQGLOKNQJWYPQ-UHFFFAOYSA-N 2-(7-ethyl-3-methyl-2H-indazol-5-yl)-1-[2-(2-phenylethyl)tetrazol-5-yl]ethanamine Chemical compound C=1C2=C(C)NN=C2C(CC)=CC=1CC(N)C(=N1)N=NN1CCC1=CC=CC=C1 DDQGLOKNQJWYPQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- RNJLEXAHBMZYGF-UHFFFAOYSA-N 4-(8-fluoro-2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1N1C(=O)NC2=C(F)C=CC=C2C1 RNJLEXAHBMZYGF-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- BVHKSDWBOVJAPM-UHFFFAOYSA-N [1-(furan-2-yl)-2-(7-methyl-1h-indazol-5-yl)ethyl] 4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxylate Chemical compound C=1C=2C=NNC=2C(C)=CC=1CC(OC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC=CO1 BVHKSDWBOVJAPM-UHFFFAOYSA-N 0.000 claims 1
- VDCXGJLJVRTRJB-UHFFFAOYSA-N [2-(7-methyl-1h-indazol-5-yl)-1-quinolin-2-ylethyl] 4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxylate Chemical compound C1=CC=CC2=NC(C(OC(=O)N3CCC(CC3)N3C(NC4=CC=CC=C4C3)=O)CC=3C=C(C=4NN=CC=4C=3)C)=CC=C21 VDCXGJLJVRTRJB-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- WPPOGGMMKNGUFR-UHFFFAOYSA-N n-[1-(5-methyl-1h-imidazol-2-yl)-2-(7-methyl-1h-indazol-5-yl)ethyl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide Chemical compound CC1=CNC(C(CC=2C=C3C=NNC3=C(C)C=2)NC(=O)N2CCC(CC2)N2C(NC3=CC=CC=C3C2)=O)=N1 WPPOGGMMKNGUFR-UHFFFAOYSA-N 0.000 claims 1
- PYRBTOMNDGHOGK-UHFFFAOYSA-N n-[1-isoquinolin-3-yl-2-(7-methyl-1h-indazol-5-yl)ethyl]-4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxamide Chemical compound C1=CC=C2C=NC(C(NC(=O)N3CCC(CC3)C=3C(NC4=CC=CC=C4C=3)=O)CC=3C=C(C=4NN=CC=4C=3)C)=CC2=C1 PYRBTOMNDGHOGK-UHFFFAOYSA-N 0.000 claims 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 17
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 17
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 15
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 15
- 206010019233 Headaches Diseases 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 4
- 102000056906 Calcitonin Receptor-Like Human genes 0.000 description 3
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 3
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 208000006561 Cluster Headache Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 108010050923 calcitonin gene-related peptide (8-37) Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000005796 circulatory shock Effects 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical class NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 1
- JUYQSMXGDBGGSX-UHFFFAOYSA-N 2-piperidin-1-yl-1h-benzimidazole Chemical class C1CCCCN1C1=NC2=CC=CC=C2N1 JUYQSMXGDBGGSX-UHFFFAOYSA-N 0.000 description 1
- WUOVJZPIPLAQBE-UHFFFAOYSA-N 4-oxobutanamide Chemical class NC(=O)CCC=O WUOVJZPIPLAQBE-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 125000001559 cyclopropyl group Chemical class [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
HETEROCYCLIC ANTI-MIGRAINE AGENTS
The present invention relates to novel small molecule antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine, cluster headache and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37- amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (®<CGRP and BCGRP) which differ by one and three amino acids in rats and humans, respectively. The peptide is widely distributed in both the peripheral (PNS) and central nervous system (CNS), principally localized in sensory afferent and central neurons, and displays a number of biological effects, including vasodilation.
When released from the cell, CGRP binds to specific cell surface G protein-coupled receptors and exerts its biological action predominantly by activation of intracellular adenylate cyclase (Poyner, D. R. et al, Br J Pharmacol 1992, 105, 441-7; Van Valen, F. et al, Neurosci Lett 1990, 119, 195-8.). Two classes of CGRP receptors, CGRP, and CGRP, have been proposed based on the antagonist properties of the peptide fragment CGRP(8-37) and the ability of linear analogues of CGRP to activate CGRP; receptors (Juaneda, C. et al. TiPS 2000, 21, 432-438). However, there is lack of molecular evidence for the CGRP, receptor (Brain, S. D. et al, TiPS 2002, 23, 51-53). The CGRP, receptor has three components: (i) a 7 transmembrane calcitonin receptor-like receptor (CRLR); (ii) the single transmembrane receptor activity modifying protein type one (RAMPL); and (iii) the intracellular receptor component protein (RCP) (Evans B. N. et al., J
Biol Chem. 2000, 275, 31438-43). RAMP is required for transport of CRLR to the plasma membrane and for ligand binding to the CGRP-receptor (McLatchie,
L. M. et al, Nature 1998, 393, 333-339). RCP is required for signal transduction (Evans B. N. et al., J Biol Chem. 2000, 275, 31438-43). There are known species- specific differences in binding of small molecule antagonists to the CGRP- receptor with typically greater affinity seen for antagonism of the human receptor than for other species (Brain, S. D. et al, TiPS 2002, 23, 51-53). The amino acid sequence of RAMP1 determines the species selectivity, in particular, the amino acid residue Trp74 is responsible for the phenotype of the human receptor (Mallee et al. J Biol Chem 2002, 277, 14294-8).
Inhibitors at the receptor level to CGRP are postulated to be useful in pathophysiologic conditions where excessive CGRP receptor activation has occurred. Some of these include neurogenic vasodilation, neurogenic inflammation, migraine, cluster headache and other headaches, thermal injury, circulatory shock, menopausal flushing, and asthma. CGRP receptor activation has been implicated in the pathogenesis of migraine headache (Edvinsson L. CNS
Drugs 2001;15(10):745-53; Williamson, D. J. Microsc. Res. Tech. 2001, 53, 167- 178.; Grant, A. D. Brit. J. Pharmacol. 2002, 135, 356-362.). Serum levels of
CGRP are elevated during migraine (Goadsby PJ, et al. Ann Neurol 1990;28:183- 7) and treatment with anti-migraine drugs returns CGRP levels to normal coincident with alleviation of headache (Gallai V. et al. Cephalalgia 1995;15: 384-90). Migraineurs exhibit elevated basal CGRP levels compared to controls (Ashina M, et al., Pain. 2000;86(1-2):133-8.2000). Intravenous CGRP infusion produces lasting headache in migraineurs (Lassen LH, et al. Cephalalgia. 2002
Feb;22(1):54-61). Preclinical studies in dog and rat report that systemic CGRP blockade with the peptide antagonist CGRP(8-37) does not alter resting systemic hemodynamics nor regional blood flow (Shen, Y-T. et al, J Pharmacol Exp Ther 2001, 298, 551-8). Thus, CGRP-receptor antagonists may present a novel treatment for migraine that avoids the cardiovascular liabilities of active vasoconstriction associated with non-selective 5-HT p/p agonists, ‘triptans’ (e.g., sumatriptan). See Olesen, et al., New England Journal of Medicine, 2004, 350 (11), 1104-1110.
A number of non-peptidic, small molecule CGRP-receptor antagonists have been recently reported. WO 97/09046 and equivalents disclose inter alia quinine and quinidine related compounds which are ligands, in particular antagonists, of CGRP-receptor. WO 98/09630 and WO 98/56779 and equivalents disclose inter alia variously substituted, nitrobenzamide compounds as CGRP-receptor antagonists. WO 01/32649, WO 01/49676, and WO 01/32648 and equivalents disclose inter alia a series of 4-oxobutanamides and related cyclopropane derivatives as CGRP-receptor antagonists. WO 00/18764, WO 08/11128 and WO 00/55154 and equivalents disclose inter alia benzimidazolinyl piperidines as antagonists to CGRP-receptor. Unrelated to CGRP, a series of somatostatin antagonists have been disclosed in WO 99/52875 and WO 01/25228 and equivalents. See also US 6,344,449, US 6,313,097, US 6,521,609, US 6,552,043, US 20030181462, US20030191068 and WO 03/076432 and related applications. Yet other CGRP-receptor antagonist and related applications include US20030139417A1, US20030181462, US20030191068A1,
US20030212057A1, US20030236282A1, US20040014679A1,
US20040076587A1, US20040132716A1, US20040192729A1,
W02004082602A2, WO2004082605A2, W0O2004082678A1,
WO02004083187A1, W02004092168A1, W0O2004092166A2 and
WO02004091514A2. A great need for the development of novel CGRP-receptor antagonists effective for the treatment of neurogenic inflammation, migraine and other disorders exists.
Thus according to a first embodiment of the first aspect of the present invention are provided compounds of Formula (I)
Q
~ AA , 4 or pharmaceutically acceptable salts or solvates thereof wherein
Vis a S-membered ring selected from the group consisting of imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, isoxazolyl, oxadiazolyl, triazolyl, thiadiazolyl and tetrazolyl; or . a 6-membered ring selected from the group consisting of pyridyl, pyrimidinyl, triazinyl, pyrazinyl, pyridazinyl and tetrazinyl; or a fused bicyclic ring system selected from the group consisting of indolyl, isoindolyl, indazolyl, benzimidazolyl, benzythiazolyl, triazolopyridinyl,imidazopyridinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and benzfuranyl; wherein V is optionally substituted with one to three of the same or different substituents selected from the group consisting of
C\4alkyl, C)salkoxy, C,shydroxyalkyl, C(O)OC:.3alkyl,
C alkylcarbonyl, carboxy, C;4alkylcarboxy, trifluoromethyl, halo, cyano, amino, amido, nitro, carbamoyl, ureido,
C,.salkylamino, C; 4dialkylamino, C;..dialkylaminoC,.,alkyl, sulphonamide and sulphonyl; and
V optionally contains 1 or 2 carbonyls; provided that if t is 1, then V is optionally substituted with one of the ubstitutents selected from the group consisting of halo,
C,4alkyl, Cy _salkylidine, salkylidine,C;4alkoxy, Cishydroxyalkyl,
C,.salkylcarbonyl, trifluoromethyl, halo and cyano; and
V optionally contains 1 or 2 carbonyls; (V"), wherein tis O or 1; and
V'is selected from the group consisting of Cs cycloalkyl, phenyl, adamantyl, quinuclidyl, azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl, : pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino and dioxolanyl; and wherein
V' is optionally substituted with 1 or 2 of the same or different substituents selected from the group consisting of halo, cyano, Cyalkyl, C)shaloalkyl,
Cialkoxy, hydroxy, amino, Cs.scycloalkyl,
C,alkylamino, C,4dialkylamino, (C1.3alkyl)g.oureido, C(O)OC;.3alkyl, carboxy, amido, nitro, phenyl and benzyl; and wherein
V' optionally contains 1 or 2 carbonyls; and
V and V' are optionally interrupted by C,_salkylene, O, -(CH2)0.2C(0)-(CH3)o.2-; or -N-Cj4alkyl, said C,_jalkylene being optionally interrupted by or having attached thereto
O,NorS;
U is CHa, O, or NH;
Qis (S*)R% $Y is C alkylene or C;.salkylidene and sis O or 1;
R*is R* or R* wherein
R*is y) a heterocycle having two fused rings with 5 to 7 members in each of said rings, said heterocycle containing one to five of the same or different heteroatoms selected from the group consisting of 0, N and S and said heterocycle optionally containing 1 or 2 carbonyls wherein the carbon atom of said carbonyl is a member of said fused rings; (ii) a4 to 6 membered heterocycle containing one to : three of the same or different heteroatoms selected from the group consisting of O, N and §, optionally containing 1 to 2 carbonyls, wherein the carbon atom of said carbonyl is a member of said 4 to 6 membered heterocycle; (iii) Cs.cycloalkyl; (iv) carbazolyl, fluorenyl, phenyl, -O-phenyl, -O-
C,.4alklylene-phenyl, or napthyl; or (v) Cisalkyl, Cp7alkenyl, -C(O)R*, CHC(O)O-R?,
CH(CH;)C(0)O-R* ,-C(0)O-R* or Cy.salkynyl; and wherein R is optionally substituted with 1 to 3 of the same or different substituents selected from the group consisting of benzyl, phenyl, -O-phenyl, -O-
C,.3alkylenephenyl, -C;.3alkylene-OC(O)-phenyl, cyano, amino, nitro, halo, C,.alkyl, C|.3mono-bi- tri-haloalkyl, C,.3mono-bi-tri-haloalkyloxy, (Ci. salkyl), ;amine, -OR®, -C(O)R”, -C(0)O-R?, -O-
C(OR®, -N®R*)2, -CONR),
NR)CO)R?)2, -NR*ICONR),
NR*)C(O)OR*, -O-C(O)N(R*),,
NR*)SO;R?, -SO:N(R*)2and -SOR’;
WQ 2005/056550 PCT/US2004/040721
R¥is H or -C, salkyl;
R*®is R* but is not said phenyl or said substituted phenyl; provided that if V and V' together form substitued or unsubstituted imidazol-2-y! or a substituted or unsubstituted fused bicyclic system containing imidazol-2-yl, then R? is R*";
D is O, NCN or NSO,C.salkyl;
Ais C,Nor CH; m and n are independently 0, 1 or 2; provided that if m and n are 0, then A is not N; if mis 2, then n is not 2; or if n is 2, then m is not 2;
Eis N,CH or C; pisQorl; if pis 1, then G, J and E together form A* or A”
A is a fused heterocycle having two fused rings with 5 to 7 members in each of said rings, said heterocycle containing one to four of the same or different heteroatoms selected from the group consisting of
O, N and S; and optionally containing 1 or 2 carbonyls wherein the carbon atom of said carbonyl is a member of said fused heterocycle;
AY is a 4 to 6 membered heterocycle containing one to three heteroatoms selected from the group consisting of O, N and S; and optionally containing 1 to 2 carbonyls, wherein the carbon atom of said carbonyl is a member of said 4 to 6 membered heterocycle;
wherein A* and AY are optionally substituted with
C,4alkyl, Ci4alkoxy, Cy.shaloalkyl, cyano,
Cs.rcycloalkyl, phenyl, halophenyl, halo, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl or morpholino; or if p is O such that G and J are each attached to A, then A is C, and : G, J and A together form a spirocyclic ring system with said rings of said system containing A and wherein GJA is
Afor A.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein m is 1 and n isl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein pis 1 and E is N.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein pis 1 and E is C.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1 and E is CH.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1 and G, J and A form a A”.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1 and G, J and A form a A” and wherein A*is a fused heterocycle with two fused rings each having 6 members.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1 and G, J and A form a A” and wherein A* is 3,4- dihydro-1H-quinazolin-2-one.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 1 and G, J and A form a AX and wherein A* is 3,4- dihydro-1H-quinazolin-2-one optionally halogenated.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is I and G, J and A form a A* and wherein A” is 8- fluoro-2-ox0-1,2-dihydroquinazolin-3(4H)-yl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 0.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 0 and G, J and A form a A™.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 0 and G, J and A form a A* and wherein A*is a fused heterocycle with two fused rings each having 6 members and where said fused heterocycle forms a spirocyclic ring system containing A.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein p is 0 and G, J and A form a A* and wherein A*is a fused heterocycle with two fused rings each having 6 members, wherein one of said 6-membered rings, Which contains A, further contains a nitrogen and an oxygen which are interrupted by a carbonyl said oxygen attached to A and wherein said fused heterocycle forms a spirocyclic ring system containing A.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein is s is 1and S” is methylene.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein is s is 1, S*is methylene and R3is R®.
According to a another emobdiment of the first aspect of the present : invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein is s is 1, S? is methylene and R® is R* wherein R¥is a heterocycle having two fused rings, one of said fused rings having six members and being attached to SY and the other of said rings having 5 members and containing two nitrogens.
According to a another emobdiment of the first aspect of the present “invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein is s is 1, SY is methylene and R® is R** wherein R*is 7- methyl-1H-indazol-5-yl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein is s is 1, Sis methylene and R? is R* wherein R*is 7- ethyl-3-methyl-1H-indazol-5-yl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein D is O and U is O.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein D is O and U is CHa.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein D is O and U is NH.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein t is 0.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein t is 1.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein t is 1 and V' is selected from the group consisting of Cs. scycloalkyl, phenyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl, pyridyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino and dioxolanyl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein t is 1 and V' is selected from the group consisting of phenyl, pyridyl and piperidinyl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein t is 1 and V' is selected from the group consisting of phenyl, pyridyl and piperidinyl and V' is substituted with 1 or 2 of the same or different substituents selected from the group consisting of halo, cyano, C,4alkyl,
C,shaloalkyl, C;4alkoxy, hydroxy, amino, Cs.icycloalkyl, C,4alkylamino,
C,«dialkylamino, (C,.salkyl)o.ureido, C(O)OC,.salkyl, carboxy, amido, nitro, phenyl and benzyl.
According to a another emobdiment of the first aspect of the present invention are compounds of Formula (I) or pharmaceutically acceptable salts or
Claims (1)
- What is claimed is:1. A compound of Formula (I) Q D AA u N A— oO 4 or a pharmaceutically acceptable salt or solvate thereof wherein Vis a S-membered ring selected from the group consisting of imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, isoxazolyl, oxadiazolyl, triazolyl, thiadiazolyl and tetrazolyl; or a 6-membered ring selected from the group consisting of pyridyl, pyrimidinyl, triazinyl, pyrazinyl, pyridazinyl and tetrazinyl; or a fused bicyclic ring system selected from the group consisting of indolyl, isoindolyl, indazolyl, benzimidazolyl, benzythiazolyl, triazolopyridinyl, imidazopyridinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and benzfuranyl; wherein V is optionally substituted with one to three of the same or different substituents selected from the group consisting ofC).salkyl, Cy 4alkoxy, C 1 shydroxyalkyl, C(0)OC:.3alkyl, Calkylcarbonyl, carboxy, Ci4alkylcarboxy, trifluoromethyl, halo, cyano, amino, amido, nitro, carbamoyl, ureido, Ci4alkylamino, C,4dialkylamino, C).4dialkylaminoC;.zalkyl, sulphonamide and sulphonyl; and V optionally contains 1 or 2 carbonyls; provided that if tis 1, then V is optionally substituted with one of the substitutents selected from the group consisting of halo,Ci4alkyl, C;.salkylidine, salkylidine,C, 4alkoxy, C,shydroxyalkyl, C4alkylcarbonyl, trifluoromethyl, halo and cyano; and V optionally contains 1 or 2 carbonyls; (V'), wherein tis O or 1; and V' is selected from the group consisting of C,.qcycloalkyl, phenyl, adamantyl, quinuclidyl, azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, piperidinyl, piperazinyl, morpholino, thiomorpholino and dioxolanyl; and wherein V' is optionally substituted with 1 or 2 of the same or different substituents selected from the group consisting of halo, cyano, Cy4alkyl, C\4haloalkyl, C, alkoxy, hydroxy, amino, C.;cycloalkyl, C1alkylamino, C,4dialkylamino,(C1.3alkyl).oureido, C(O)OC; salkyl, carboxy, amido, nitro, phenyl and benzyl; and wherein V' optionally contains 1 or 2 carbonyls; and V and V' are optionally interrupted by Ci.;alkylene, oO, -(CH2)0.2C(0)-(CHz)o-2= or -N-Cy.salkyl, said C,.salkylene being optionally interrupted by or having attached thereto O,NorS; U is CHa, O, or NH; Qis (SMR; wherein S? is C;.salkylene or C,.salkylidene and s isOor1l; R*isR® orR® whereinR*is 1) a heterocycle having two fused rings with 5 to 7 members in each of said rings, said heterocycle containing one to five of the same or different heteroatoms selected from the group consisting of O, N and S and said heterocycle optionally containing 1 or 2 carbonyls wherein the carbon : atom of said carbonyl is a member of said fused rings; (ii) a4 to 6 membered heterocycle containing one to three of the same or different heteroatoms selected from the group consisting of O, N and S, optionally containing 1 to 2 carbonyls, wherein the carbon atom of said carbonyl is a member of said 4 to 6 membered heterocycle; . (ili) Cs.ocycloalkyl; (iv) carbazolyl, fluorenyl, phenyl, -O-phenyl, -O- C,alklylene-phenyl, or napthyl; or ) Cisalkyl, Czalkenyl, -C(O)R?, CHC(O)O-R?, CH(CH;3)C(0)O-R*,-C(0)O-R* or Cyqalkynyl; and wherein R* is optionally substituted with 1 to 3 of the same or different substituents selected from the group consisting of benzyl, phenyl, -O-phenyl, -O-C,.salkylenephenyl, -C,.3alkylene-OC(O)-phenyl, cyano, amino, nitro, halo, Cyalkyl, C,.3mono-bi- tri-haloalkyl, C;.3mono-bi-tri-haloalkyloxy, (Ci. jalkyl),.;amine, -OR?,-C(O)R?, -C(0)O-R*, -O-C(O)R”, NR). C(ONR®)2, NR*)CO)R* 2. - NR*ICONR®),, -NR*)C(O)OR*, -O-C(ONR®),, -NR*)SO:R?,-SO,N(R*),and -SOR*; R¥'is H or -C; alkyl; Ris R* but is not said phenyl or said substituted phenyl;provided that if V and V' together form substitued or unsubstituted imidazol-2-yl or a substituted or unsubstituted fused bicyclic system containing imidazol-2-yl, then R® is R®;D is O, NCN or NSO,C;.salkyl; Ais C,N or CH; : m and n are independently 0, 1 or 2; provided that if m and n are 0, then A is not N; if m is 2, then n is not 2; or if n is 2, then m is not 2; EisN,CHorC; pisOorl; if pis 1, then G, J and E together form Aor A A* is a fused heterocycle having two fused rings with 5 to 7 members in each of said rings, said heterocycle . containing one to four of the same or different heteroatoms selected from the group consisting of O, Nand S; and ) optionally containing 1 or 2 carbonyls wherein the carbon atom of said carbonyl is a member of said fused heterocycle; A’ is a 4 to 6 membered heterocycle containing one to three heteroatoms selected from the group consisting of O, N and S; and optionally containing 1 to 2 carbonyls, wherein the carbon atom of said carbonyl! is a member of said 4 to 6 membered heterocycle; wherein A*and A’ are optionally substituted with Csalkyl, C; alkoxy, Ci.shaloalkyl, cyano,Cs.cycloalkyl, phenyl, halophenyl, halo, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny), imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, : pyridyl, pyrimidinyl, piperidinyl, piperazinyl or morpholino; or if p is 0 such that G and J are each attached to A, then A is C, and G, J and A together form a spirocyclic ring system with said rings of said system containing A and wherein GJA is Ator A’.2. A compound according to claim 1 wherein mis 1 and nisl.3. A compound according to claim 1 wherein pis 1. i 4, A compound according to claim 1 wherein pis 1 and Eis N.5. A compound according to claim 1 wherein pis 1and Eis C.6. A compound according to claim 1 wherein p is 1 and E is CH.7. A compound according to claim 1 wherein pis 1 and G, J and A form a A%8. A compound according to claim 1 wherein p is 1 and G, J and A form a A* and wherein A” is a fused heterocycle with two fused rings each having 6 members. Oo A compound according to claim 1 wherein p is 1 and G, J and A form a A” and wherein A* is 3,4-dihydro-1H-quinazolin-2-one.10. A compound according to claim 1 wherein p is1 and G, J and A form a A* and wherein A* is 3,4-dihydro-1H-quinazolin-2-one optionally halogenated.11. A compound according to claim 1 wherein p is 1 and G,J and A form a A* and wherein A’ is 8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl.12. A compound according to claim 1 wherein p is 0.13. A compound according to claim 1 wherein p is 0 and G, J and A form aA*.14. A compound according to claim 1 wherein p is0and G,J and A form a A* and wherein A*is a fused heterocycle with two fused rings each having 6 members and where said fused heterocycle forms a spirocyclic ring system containing A.15. A compound according to claim 1 wherein p is 0 and G, J and A form a A* and wherein Ais a fused heterocycle with two fused rings each having 6 members, wherein one of said 6-membered rings, which contains A, further contains a nitrogen and an oxygen which are interrupted by a carbonyl said oxygen attached to A and wherein said fused heterocycle forms a spirocyclic ring system containing A.16. A compound according to claim 1 wherein s is land S’ is methylene.17. A compound according to claim 1 wherein is s is 1, SY is methylene and Ris R®.18. A compound according to claim 1 wherein is s is 1, SY is methylene and R%is R* wherein R* is a heterocycle having two fused rings, one of said fused rings having six members and being attached to SY and the other of said rings having 5 members and containing two nitrogens.19. A compound according to claim 1 wherein is s is 1, S” is methylene and R3is R% wherein R* is 7-methyl-1H-indazol-5-yl.20. A compound according to claim 1 wherein is s is 1, $7 is methylene and R3is R* wherein R* is 7-ethyl-3-methyl-1H-indazol-5-yl.21. A compound according to claim 1 wherein D isO and Uis O.22. A compound according to claim 1 wherein D is O and U is CHa.23. A compound according to claim 1 wherein D is O and U is NH.24. A compound according to claim 1 wherein t is 0.25. A compound according to claim 1 wherein tis 1.26. A compound according to claim 1 wherein tis 1 and V' is selected from the group consisting of Cs.scycloalkyl, phenyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl,pyranyl, pyridyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino and dioxolanyl.27. A compound according to claim 1 wherein tis 1 and V' is selected from the group consisting of phenyl, pyridyl and piperidinyl.28. A compound according to claim 1 wherein tis 1 and V' is selected from the group consisting of phenyl, pyridyl and piperidinyl and V' is substituted with 1 or 2 of the same or different substituents selected from the group consisting of halo, cyano, C1 4alkyl, C, shaloalkyl, C;4alkoxy, hydroxy, amino, Cs.scycloalkyl, C4alkylamino, C;4dialkylamino, (C1-3alkyl)ooureido, C(O)OC:salkyl, carboxy, amido, nitro, phenyl and benzyl.29. A compound according to claim 1 wherein t is 1 and V' is selected from the group consisting of phenyl, pyridyl and piperidinyl and V'is substituted with 1 or 2 of the same or different substituents selected from the group consisting of C;_«dialkylamino, C(0)OC,.3alkyl, carboxy, amido, nitro and phenyl.30. A compound according to claim 1 wherein V is said 5-membered ning.31. A compound according to claim 1 wherein V is said 6-membered ring.32. A compound according to claim 1 wherein V is said fused bicyclic ring system.33. A compound according to claim 1 wherein V is furanyl, imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine, quinolinyl, Cj alkylcarbonyl, carboxy, indazolyl, triazolopyridinyl or imidazopyridinyl.34. A compound according to claim 1 wherein V contains a carbonyl.35. A compound according to claim 1 wherein V is furanyl, imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine, quinolinyl, C,.salkylcarbonyl, carboxy, indazolyl or [1,2,4]Triazolo[4,3-a]pyridin-3-yl or H- ‘Imidazo[1,5-a]pyridin-3-yl).36. A compound according to claim 1 wherein V and V' are interrupted by methylene, ethylene and -(CH2)p2C(O)-(CH2)o-2--37. A compound according to claim 1 wherein V and V' are interrupted by methylene, ethylene and -(CH3)0.2C(0)-(CHy)o.2- wherein said interrupting substituents are unsubstituted.38. A compound according to claim 1 wherein s is 1, S? is methylene and Ris R* wherein R*is an optionally C)_salkyl-substituted indazolyl; U is CHa, O, or NH; Dis O; A is CH; m and n are each 1; Eis N; pis 1; and G, J and E together form A”, wherein A’is an optionally halogenated dihydroquinazolinone.39. A compound according to claim 1 wherein V is furanyl, imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine, quinolinyl, C,.salkylcarbonyl, carboxy, indazolyl, triazolopyridinyl or imidazopyridinyl; tisOorl;V' is selected from the group consisting of phenyl, pyridyl and piperidinyl and V' is substituted with 1 or 2 of the same or different substituents selected from the group consisting of C,4dialkylamino, C(0)OC;.3alkyl, carboxy, amido, nitro and phenyl; wherein V and V' are interrupted by methylene, ethylene and - (CH2)0.2C(0)-(CHz)o.o- wherein said interrupting substituents are unsubstituted; sis 1, S? is methylene and R?is R* wherein R*is an optionally C;salkyl-substituted indazolyl; U is CH,, O, or NH; Dis O; Ais CH; m and n are each 1; Eis N; pis 1; and G, J and E together form A*, wherein A” is an optionally halogenated dihydroquinazolinone.40. (®)-3-{ 1-{4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin- 4-yl}-3,4-dihydro-1H-quinazolin-2-one; (+)-3-{1-[3-(3-Benzyl-[1 2,4]oxadiazol-5-yl)-4-(7-methyl-1H-indazol-5-yl)- butyryl]-piperidin-4-yl}-3,4-dihydro-1 H-quinazolin-2-one; *)-3-{ 1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-piperidin-1 -ylmethyl- [1,2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl }-3.4-dihydro-1H-quinazolin-2-one; (2)-3-{1-[4-(7-Methyl-1 H-indazol-5-yl)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)- butyryl]-piperidin-4-yl }-3,4-dihydro-1H-quinazolin-2-one; (%)-3-{ 1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-methyl-[1 .2,4Joxadiazol-5-yl)- butyryl]-piperidin-4-yl }-3,4-dihydro-1H-quinazolin-2-one; (£)-3-{ 1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-pyridin-4-ylmethyl- [1 2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl }-3,4-dihydro-1H-quinazolin-2-one;(x)-3-{1-[3-(3 -Dimethylaminomethyl-[1,2,4)oxadiazol-5-yl)-4-(7 -methyl-1H- indazol-5-yl)-butyryl]-piperidin-4-yl }-3,4-dihydro-1H-quinazolin-2-one; (£)-3-{1-[3-(3-Benzyl-[1 ,2,4]Joxadiazol-5-y1)-4-(7-methyl-1 H-indazol-5-yl)- butyryl]- 4,4"-piperidinyl }-1 2'-dihydro-2'-oxospiro-[4H-3',1-benzoxazine;(2)-3-{ 1-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl- 1H-indazol-5-yl)- butyryl]- 4,4'-piperidinyl }-1 + 2_dihydro-2'-oxospiro-[4H-3',1-benzoxazine; (£)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [1- (3-benzyl-[1,2,4]0xadiazol-5-yl)-2-(7-methyl-1H-indazol-5-yD)-ethyl]-amide;(£)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2-(7-methyl-1H-indazol-5-yl)-1 -(3-methyl-[1 ,2,4Joxadiazol-5-yl)-ethyl]-amide; - (x)-4-(2-Oxo0-1 .4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2- (7-methyl-1H-indazol-5-y1)-1 -(3-pyridin-4-ylmethyl-{1 ,2,4]oxadiazol-5-yl)- ethyl]-amide; ()-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [1-(3-dimethylaminomethyl-[1 2 4loxadiazol-5-yl)-2-(7-methyl-1H-indazol-5-yl)-ethyl]-amide; (4)-4-(2-Oxo-1 4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2- (7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-ethyl]-amide; (#)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine- 1-carboxylic acid [2-(7-ethy)-3-methyl-1H-indazol-5-yl)-1-(phenethyl-1H-tetrazol-5-yl)-ethyl]-amide;(4)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2- (7-ethyl-3-methyl-1H-indazol-5-yl)-1-(2-phenethyl-2H-tetrazol-5-yl)-ethyl]- amide;(+)-4-(2-Oxo-1 4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2-(7-ethyl-3-methyl-1 H-indazol-5-yl)-1-(1-methyl- 1H-tetrazol-5-yl)-ethyl]-amide;(#)-4-(2-Oxo-1 ,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [1- (1-benzyl-1H-tetrazol-5-yl)-2-(7 -ethyl-3-methyl-1H-indazol-5 -yl)-ethyl]-amide; (+)-4-(2-Ox0-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2- (7-ethyl-3-methyl-1H-indazol-5-yl)-1-pyridin-4-yl methyl-1H-tetrazol-5-yl)-ethyl]-amide;(1)-4-(2-Ox0-1 4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid [2- (7-ethyl-3-methyl-1H-indazol-5-y1)-1-(2-oxo-2Phenethyl-2H-tetrazol-5-yl)- ethyl]-amide;(1)-4-(2-Oxo-1 4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicacid [2-(7-ethyl-3-methyl- 1H-indazol-5-y1)-1-{1-(2-ox0-2-phenyl-ethyl)- 1H-tetrazol-5-y1)- ethyl}-amide;: (4)-3-(1-(3-(4-Ethylpyridin-2-y1)-4-(7-methyl- 1H-indazol-5- ylbutanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one; (+)-8-Fluoro-3-(1-(4-(7-methyl-1H-indazol-5-y})-3-(pyridin-2-ylbutanoylpiperidin-4-yl)-3 4-dihydroquinazolin-2(1H)-one; (#)-3-(1-(4-(7-Methyi-1 H-indazol-5-yl)-3-(pyridin-2-yl)butanoyl)piperidin-4- yhquinolin-2(1H)-one; ()-3-(1-(4-(7-Methyl-1H-indazol-5-y1)-3-(3-methylpyridin-2- yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;()-3-(1-(4-(7-Methyl-1H-indazol-5-y})-3-(5-methylpyridin-2- y)butanoyl)piperidin-4-yl)-3,4-dihydroguinazolin-2(1H)-one; (2)-3-(1-(3-(5-(Hydroxymethyl)pyridin-2-y!)-4-(7-methyl-1H-indazol-5- yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;(1)-6-(1 -(7-Methyl- 1H-indazol-5-yl)-4-0x0-4-(4-(2-0xo- 1,2-dihydroquinazolin-3(4H)-yl)piperidin-1-yl)butan-2-yDnicotinaldehyde; (£)3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(5-(piperidin-1-ylmethyl)pyridin-2- yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one; ()-N-(1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-ylethyl)-4-(2-0xo- 1 ,2-dihydroquinazolin-3(4H)-yl)piperidine-1 carboxamide;(#)-N-(2-(7-Methyl-1 H-indazol-5-y1)-1 -(pyridin-2-yl)ethyl)-4-(2-oxo0- 1,2- dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide; (£)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(4-nitropyridin-2-yl)ethyl)-4-(2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide; (@)-N-(1-(4-Fluoropyridin-2-yl)-2-(7-methyl- 1H-indazol-5-yl)ethyl)-4-(2-oxo-1 2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;(£)-N-(2-(7-Methyl-1H-indazol-5-yl)-1 -(quinolin-2-yl)ethyl)-4-(2-oxo-1 2- dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide; ()-4-(8-Fluoro-2-ox0-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-(7-methyl-1 H- indazol-5-y1)-1-(quinolin-2-yl)ethyl)piperidine- 1-carboxamide;N-(1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1 ,2- dihydroquinolin-3-yl)piperidine-1 -carboxamide; (£)-N-(2-(7-Methyl-1H-indazol-5-y1)-1 -(6-phenylpyridin-2-yhethyl)-4- (2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide;(2)-N-(2-(7-Methyl-1H-indazol-5-y})- 1-(6-methylpyridin-2-yl)ethy})-4-(2-oxo0- 1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;H)-1 -(6-Bromopyridin-2-yl)-2-(7-methyl-1 H-indazol-5-yl)ethyl-4-(8-fluoro-2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;(#)-1 -(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl-4-(2-0xo- 1,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate;(#1 -(6-tert-Butoxypyridin-2-y1)-2-(7 -methyl-1H-indazol-5 -yl)ethyl-4-(2-ox0-- 1,2-dihydroquinazolin-3(4H)-yl)piperidine-1 carboxylate;(+)-2-(7-Methyl- 1H-indazol-5-yl)-1 -(6-0x0-1,6-dihydropyridin-2-ylethyl 4-(2- oxo-1,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxylate; @)- 1-(6-Isobutylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-ylethyl 4-(8-fluoro-2-oxo-1 2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate; ®)-1 -(6-(3,5-Difluorobenzyl)pyridin-2-y1)-2-(7-methyl-1H-indazol-5-yl)ethyl 4- (8-fluoro-2-oxo-1 2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;#*)-1 -(6-Cyanopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yDethyl 4-(8-fluoro-2- oxo-1 2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;(B)-1 -(4-(Hydroxymethyl)pyridin-2-yl)-2-(7-methyl-1H-indazol-5-yDethyl 4-(2- oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate; ()-1-(4-Formylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-yDethyl 4-(2-0x0-1,2- dihydroguinazolin-3(4H)-yl)piperidine-1-carboxylate;(3)-2-(2-(7-Methyl-1 H-indazol-5-yl)-1-(4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine-1 -carbonyloxy)ethyl)isonicotinic acid;(£)-2-(7-Methyl-1H-indazol-5-yl)-1 -(4-(piperidine-1 -carbonyl)pyridin-2-yl)ethyl 4-(2-o0x0-1 ,2-dihydroquinazolin-3(4H)-yl)piperidi ne-1-carboxylate; N-(1-(isoquinolin-3-y1)-2-(7-methyl- 1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxamide;S 4-(8-fluoro-2-oxo-1 ,2-dihydroquinazolin-3(4H)-y1)-N-(1 -(isoquinolin-3-yl)-2-(7- methyl-1H-indazol-5-yl)ethyl)piperidine- 1-carboxamide;1-(Isoquinolin-3-y1)-2-(7-methyl- 1H-indazol-5-y})ethyl 4-(8-fluoro-2-oxo-1,2- dihydroquinazolin-3 (4H)-y))piperidine-1-carboxylate; 1-(Isoquinolin-3-y1)-2-(7-methyl-1H. -indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1 carboxylate; 2-(7-methyl-1H-indazol-5-y})-1 ~(pyridin-2-yl)ethyl 4-(2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxylate; 2-(7-methyl-1H-indazol-5-yl)-1 (pyridin-2-yDethy} 4-(8-fluoro-2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxylate;1-(Furan-2-yl)-2-(7-methyl-1 H-indazol-5-yl)ethyl 4-(2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate; 2-(7-Methyl-1H-indazol-5-y})-1 ~(pyridin-4-ylethyl 4-(2-oxo-1 2- dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate; 2-(7-Methyl-1H-indazol-5-yl)-1 -(pyridin-3-ylethyl 4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate; 2-(7-Methyl-1H-indazol-5-yl)-1 ~(pyridin-3-yDethyl 4-(8-fluoro-2-oxo- 1,2- dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxylate;1-(Furan-2-yl)-2-(7-methyl-1H-indazol-5 -ylethyl 4-(8-fluoro-2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxylate;2-(7-Methyl-1H-indazol-5-yl)-1 -(quinolin-2-yl)ethyl 4-(2-oxo- 1,2- dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxylate;1-(4,6-Dimethylpyrimidin-2-y1)-2-(7 -methyl-1H-indazol-5-yl)ethyl 4-(2-oxo- 1,2- dihydroquinolin-3-yl)piperidine-1 -carboxylate; 1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1 H-indazol-5-yl)ethyl 4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3 (4H)-y))piperidine-1-carboxylate;1 -(Benzofuran-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl 4-(2-0x0-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxylate; (2)-N-(1-(1H-Imidazol-2-y1)-2-(7-methyl-1H-indazol-5 -yl)ethyl)-4-(2-oxo-1,2- dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxamide;(2)-N-(1-(1-Methyl-1 H-imidazol-2-yl)-2-(7-methyl-1 H-indazol-5-yl)ethyl)-4-(2- oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine- I-carboxamide; (2)-N-(1-(1-Benzyl-1 H-imidazol-2-yl)-2-(7 -methyl-1H-indazol-5 -yl)ethyl)-4-(2- oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (£)-N-(1-(1-(3-Fluorobenzyl)- 1H-imidazol-2-yl)-2-(7-methyl- 1H-indazol-5-ylethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine-1 -carboxamide; : (£)-N-(1-(1-(3,5-Difluorobenzyl)-1 H-imidazol-2-y1)-2-(7-methyl-1 H-indazol-5- yDethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (+)-N-(2-(7-Methyl-1H-indazol-5-y1)-1-(1 -phenethyl-1 H-imidazol-2-yl)ethyl)-4- (2-oxo-1,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxamide;(£)-N-(1-(1-(2-Fluorobenzyl)-1 H-imidazol-2-y1)-2-(7-methyl-1H-indazol-5- yDethyl)-4-(2-0x0-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (2)-N-(1-(1-(4-Fluorobenzyl)-1 H-imidazol-2-yl)-2-(7-methyl-1 H-indazol-5- yl)ethyl)-4-(2-0x0-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (£)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1 -(pyridin-4-ylmethyl)-1H-imidazol-2-yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (£)-N-(1-(1-(3-Cyanobenzyl)-1 H-imidazol-2-yl)-2-(7-methyl-1 H-indazol-5- yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidi ne-1-carboxamide;(2)-N-(1-(1-(4-tert-Butylbenzy!l)- 1H-imidazol-2-yl)-2-(7-methyl- 1H-indazol-5- yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide;(£)-3-((2-(2-(7-Methyl-1 H-indazol-5-yl)-1-(4-(2-oxo-1 ,2-dihydroquinazolin- 3(4H)-yl)piperidine-1 -carboxamido)ethyl)-1H-imidazol-1 -yl)methyl)benzoic acid;(2)-N-(1-(1-(3-Carbamoylbenzyl)-1 H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5- yl)ethyl)-(2-ox0-1 ,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxamide;(R)-1-(1-(3,5-difluorobenzyl)- 1H-imidazol-2-yl)-2-(7-methyl-1 H-indazol-5- yDethyl 4-(2-oxo-1 ,2-dihydroquinolin-3-yl)piperidine-1 -carboxylate;(2)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1 -(2-nitrophenyl)-1H-imidazol-2- yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yDpi peridine-1-carboxamide; (R)-1-(1-(3,5-difluorobenzyl)-1 H-imidazol-2-yl)-2-(7-methyl- 1H-indazol-5- yhethyl 4-(2-oxo-1 ,2-dihydroquinolin-3-yl)piperidine-1 -carboxylate;S (2)-N-(2-(7-Methyl-1H-indazol-5-y1)-1 -(1-(2-nitrophenyl)-1H-imidazol-2- yhethyl)-4-(2-0xo-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (2)-4-(8-Fluoro-2-oxo-1 ,2-dihydroquinazolin-3 [4H]-yl)-N-(2{7-methyl-1H- indazol-5-yl}-1-{ 1H-tetrazol-5-yl }ethyl)piperidin-1 -carboxamide;(+)-4-(8-Fluoro-2-oxo-1 ,2-dihydroquinazolin-3 (4H)-y1)-N-(2-[7-methyl-1 H-indazol-5-yll-1-[1 -(piperidin-4-ylmethyl)-1 H-tetrazol-5-yl]ethyl)piperidin-1- carboxamide;(+)-4-(8-Fluoro-2-oxo-1 ,2-dihydroquinazolin-3(4H)-yl)-N-(2- [7-methyl-1H- indazol-5-yl]-1-[2-(piperidin4-ylmethyl)-1 H-tetrazol-5-ylJethyl)piperidin-1- carboxamide;(&)-N-(1-([1,2,4]Triazolo[4,3-a]pyridin-3 -yl)-2-(7-methyl-1 H-indazol-5-yl)ethyl)- 4-(8-fluoro-2-oxo-1 ,2-dihydroguinazolin-3(4H)-yl)piperidine-1 -carboxamide; (2)-N-(2-(7-Methyl-1 H-indazol-5-yl)-1-(1-neopentyl-1 H-tetrazol-5-yl)ethyl)-4- (2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (R)-N-(1-(H-Imidazo[1,5-a)pyridin-3-y1)-2-(7 -methyl- 1H-indazol-5-yl)ethyl)-4-(2-0x0-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide; (#)-N-(1-(4-Bromo-1 H-imidazol-2-y1)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2- oxo-1,2-dibydroquinazolin-3(4H)-yl)piperidine-1 -carboxamide; (x)-N-(1-(4,5-Dibromo-1 H-imidazol-2-y1)-2-(7-methyl-1 H-indazol-5-yl)ethyl)-4- (2-oxo0-1,2-dihydroquinazolin-3 (4H)-yb)piperidine-1-carboxamide;(#)-N-(1-(1-(3,5-Difluorobenzyl)-5-bromo- 1H-imidazol-2-yl)-2-(7-methyl-2H- indazol-5-yl)ethyl)-4-(2-ox0-1 ,2-dihydroquinazolin-3(4H)-yl)piperidine- 1- carboxamide;(2)-N-(1-(1-(3 -Fluorobenzyl)-4-methyl-1 H-imidazol-2-yl)-2-(7-methyl-1H- indazol-5-yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)-yD)piperidine- 1- carboxamide;(+)-N-(1-(4-Methyl- 1H-imidazol-2-yl)-2-(7-methyl- 1H-indazol-5-yl)ethyl)-4-(2- oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine- 1-carboxamide; (£)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1 -(pyridin-3-ylmethyl)-1 H-imidazol-2- yhethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3 (4H)-yl)piperidine-1 carboxamide;S (x)-N-(2-(7-Methyl-1H-indazol-5-y1)-1-(1 -(pyridin-2-ylmethyl)-1 H-imidazol-2- yhethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3 (4H)-yl)piperidine-1 -carboxamide; ()-N-(1-(1 ~((2-Chloro-6-methylpyridin-4-yhmethyl)- 1H-imidazol-2-y1)-2-(7- methyl- 1H-indazol-5-yl)ethyl)4-(2-oxo-1 ,2-dihydroquinazolin-3(4H)- yl)piperidine- 1-carboxamide;: 10 (4£)-N-(2-(7-Methyl- 1H-indazo!-5-y})-1-(1-((2-methylpyridin-4-yhmethyl)- 1H- imidazol-2-yl)ethyl)-4-(2-oxo-1 ,2-dihydroquinazolin-3 (4H)-yD)piperidine-1- carboxamide; 3-(1-(3-(1-(4-tert-Butylbenzyl)- 1H-imidazol-2-yl)-4-(7-methyl-3a,7 a-dihydro- 1H-indazol-5-yl)butanoyl)piperidin-4-y1)-3 ,4-dihydroquinazolin-2(1H)-one;3-(1-(3-(1-(4-tert-Butylbenzyl)- 1H-imidazol-2-yl)-4-(7-methyl-3a,7 a-dihydro- 1H-indazol-5-yl)butanoyl)piperidin-4-y1)-8-fluoro-3 ,4-dihydroquinazolin-2(1H)- one; 3-(1-(4-(7-Methyl-3a,7a-dihydro-1 H-indazol-5-yl)-3-(1-(pyridin-4-ylmethyl)-1 H- imidazol-2-yl)butanoyl)piperidin-4-yl)-3 ,A-dihydroquinazolin-2(1H)-one;3-(1-(3-(1 H-Benzo{d]imidazol-2-yl)-4-(7 -methyl-3a,7a-dihydro-1 H-indazol-5- yl)butanoyl)piperidin-4-yl)-3 ,A-dihydroquinazolin-2(1H)-one; 3-(1-(3-(1-Ethyl-1 H-benzo[d}imidazol-2-yl)-4-(7-methyl-3 a,7a-dihydro-1H- indazol-5-yl)butanoyl)piperidin-4-yl)-3 ,4-dihydroquinazolin-2(1H)-one; (R)-1-(3-(4-Fluorophenyl)-1 2,4-0xadiazol-5-y1)-2-(7-methyl- 1H-indazol-5-ylethyl 4-(2-oxo0-1 ,2-dihydroquinolin-3-yl)piperidine- 1-carboxylate; (R)-2-(7-Methyl-1H-indazol-5-yD)-1 -(3-(pyridin-4-yl)-1 ,2,4-oxadiazol-5-yl)ethyl 4-(2-0xo-1,2-dihydroquinazolin-3(4H)- yl)piperidine-1-carboxylate; (R)-2-(7-Methyl-1H-indazol-5-y1)-1-(3 ~(pyridin-3-yl)-1 ,2,4-oxadiazol-5-yl)ethyl 4-(2-oxo-1 ,2-dihydroquinolin-3-yl)piperidine- 1-carboxylate; or(R)-1-(3-(Ethoxycarbonyl)-1 2,4-oxadiazol-5-yl)-2-(7-methyl- 1H-indazol-5- yl)ethyl 4-(2-oxo-1 2-dihydroquinolin-3-yl)piperidine-1 -carboxylate;PCT/US2004/040721 or a pharmaceutically acceptable salt or solvate thereof.4]. A compound selected from the group consisting of Examples 1-103 having an IC50 of less than 10 nM.42. A pharmaceutical composition comprising a compound according to claim 1.43. Use of a compound according to claim 1 in the manufacture of a medicament for treating migraine in a patient in need thereof.44. A compound according to any one of claims 1 to 41, substantially as herein : described with reference to and as illustrated in any of the examples. 45, A composition according to claim 42, substantially as herein described with reference to and as illustrated in any of the examples.46. Use according to claim 43, substantially as herein described with reference to and as illustrated in any of the examples. - 226 - AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52743803P | 2003-12-05 | 2003-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604543B true ZA200604543B (en) | 2007-11-28 |
Family
ID=37722569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604543A ZA200604543B (en) | 2003-12-05 | 2006-06-02 | Heterocyclic anti-migraine agents |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1914193A (en) |
ZA (1) | ZA200604543B (en) |
-
2004
- 2004-12-06 CN CN 200480041407 patent/CN1914193A/en active Pending
-
2006
- 2006-06-02 ZA ZA200604543A patent/ZA200604543B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1914193A (en) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006124026A (en) | HETEROCYCLIC AGENTS AGAINST MIGRAINE | |
US10174027B2 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | |
JP6348891B2 (en) | CXCR4 receptor antagonist | |
TWI308151B (en) | Calcitonin gene related peptide receptor antagonists | |
ZA200407902B (en) | Tri-substituted hetreroaryls and methods of makingand using the same. | |
JP6117235B2 (en) | Use of inhibitors of PI3K activity or function | |
JP2016519096A5 (en) | ||
HRP20171670T1 (en) | Compounds and compositions for modulating egfr activity | |
JP2014500323A5 (en) | ||
JP2013539777A5 (en) | ||
JP2005538959A5 (en) | ||
JP2006503010A5 (en) | ||
RU2020112759A (en) | Heterocyclic Compounds as PAD Inhibitors | |
KR20150003743A (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
JP2004523546A5 (en) | ||
CZ292707B6 (en) | Imidazole derivatives and pharmaceutical formulation in which the derivatives are comprised | |
KR20140113667A (en) | Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | |
WO2006044509A2 (en) | Methods of treating vascular injuries | |
JP2009521445A (en) | Combination of H3 antagonist / inverse agonist and appetite suppressant | |
JP2018507235A (en) | Sterol regulatory element binding protein (SREBP) inhibitor | |
EP1689493A1 (en) | Calcitonin gene related peptide receptor antagonists | |
CN101501009A (en) | CGRP receptor antagonists | |
PL183767B1 (en) | 1-(1,2-disubstituted)(condensed) derivatives of-4-(imidazol)-piperidine | |
JP2019520412A5 (en) | ||
JP2008521825A (en) | Muscarinic receptor modulators |